Halozyme Therapeutics, Inc. (HALO)
110.42
+0.58
(+0.53%)
USD |
NASDAQ |
Oct 09, 16:00
110.50
+0.08
(+0.07%)
After-Hours: 06:06
Halozyme Therapeutics Free Cash Flow (Quarterly) : 236.72M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 236.72M |
| March 31, 2026 | 176.34M |
| December 31, 2025 | 217.60M |
| September 30, 2025 | 175.57M |
| June 30, 2025 | 98.15M |
| March 31, 2025 | 153.27M |
| December 31, 2024 | 175.42M |
| September 30, 2024 | 113.86M |
| June 30, 2024 | 53.21M |
| March 31, 2024 | 125.88M |
| December 31, 2023 | 99.76M |
| September 30, 2023 | 129.47M |
| June 30, 2023 | 68.46M |
| March 31, 2023 | 75.59M |
| December 31, 2022 | 80.11M |
| September 30, 2022 | 68.63M |
| June 30, 2022 | 39.26M |
| March 31, 2022 | 47.31M |
| December 31, 2021 | 82.36M |
| September 30, 2021 | 121.24M |
| June 30, 2021 | 36.36M |
| March 31, 2021 | 58.03M |
| December 31, 2020 | 49.22M |
| September 30, 2020 | 5.908M |
| June 30, 2020 | 2.779M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.958M |
| December 31, 2019 | -27.27M |
| September 30, 2019 | -30.69M |
| June 30, 2019 | -26.15M |
| March 31, 2019 | -5.351M |
| December 31, 2018 | 7.389M |
| September 30, 2018 | -19.26M |
| June 30, 2018 | -19.28M |
| March 31, 2018 | -23.02M |
| December 31, 2017 | 152.39M |
| September 30, 2017 | 20.10M |
| June 30, 2017 | -17.23M |
| March 31, 2017 | -22.56M |
| December 31, 2016 | -16.21M |
| September 30, 2016 | -9.172M |
| June 30, 2016 | -14.01M |
| March 31, 2016 | -14.12M |
| December 31, 2015 | -16.83M |
| September 30, 2015 | -17.32M |
| June 30, 2015 | 8.678M |
| March 31, 2015 | -13.97M |
| December 31, 2014 | -1.175M |
| September 30, 2014 | -13.55M |
| June 30, 2014 | -16.12M |
| March 31, 2014 | -18.04M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AVITA Medical, Inc. | -3.742M |
| Iovance Biotherapeutics, Inc. | -66.28M |
| Merck & Co., Inc. | 4.477B |
| Incyte Corp. | 495.25M |
| Agenus, Inc. | -31.20M |